Search

Search Constraints

You searched for: Author/Creator Stagno, Fabio

Search Results

1. A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line. Issue 1 (18th November 2016)

2. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Issue 10 (October 2015)

3. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. Issue 10 (10th September 2015)

4. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Issue 3 (17th April 2019)

5. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis. Issue 7 (28th April 2018)

6. COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. (11th October 2021)

7. Dasatinib first-line: Multicentric Italian experience outside clinical trials. (January 2016)

8. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. (4th April 2019)

9. Health‐related quality of life in patients with chronic myeloid leukemia receiving first‐line therapy with nilotinib. Issue 10 (2nd March 2018)